Mometasone furoate monohydrate nasal spray for the treatment of nasal congestion in allergic rhinitis

Expert Review of Clinical Immunology

Volumn 4, Issue 2, 2008, Pages 143-155

  Nayak, Anjuli S ^a  

^a Sneeze Wheeze and Itch Associates LLC   (United States)

Author keywords

Allergic rhinitis; Intranasal corticosteroids; Mometasone furoate; Nasal congestion

Indexed keywords

ACRIVASTINE PLUS PSEUDOEPHEDRINE; ADESLORATADINE PLUS PSEUDOEPHEDRINE; ANTIHISTAMINIC AGENT; AZELASTINE; BETAMETHASONE; BUDESONIDE; CETIRIZINE PLUS PSEUDOEPHEDRINE; CHLORPHENIRAMINE; CLARITIN D; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DESLORATADINE; DEXAMETHASONE; DIPHENHYDRAMINE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; IPRATROPIUM BROMIDE; LEVOCABASTINE; MOMETASONE FUROATE; MONTELUKAST; NOSE SPRAY; OMALIZUMAB; PLACEBO; PRANLUKAST; TRIAMCINOLONE ACETONIDE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BITTER TASTE; BLOOD TINGED MUCUS; BONE METABOLISM; BURNING SENSATION; CLINICAL TRIAL; COUGHING; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSMENORRHEA; ENDOCRINE DISEASE; EPISTAXIS; GROWTH RETARDATION; HAY FEVER; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SUPPRESSION; INSOMNIA; MONOTHERAPY; MUSCULOSKELETAL PAIN; NERVOUSNESS; NOSE CONGESTION; NOSE POLYP; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PERENNIAL RHINITIS; PHARMACODYNAMICS; PHARYNGITIS; PSYCHOMOTOR DISORDER; RECOMMENDED DRUG DOSE; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; SOMNOLENCE; STINGING SENSATION; SYMPTOM; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

EID: 46149119658     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.4.2.143     Document Type: Article

References (96)

1. Bousquet J, van Cauwenberge P, Khaltaev N; ARIA Workshop Group; World Health Organization. Allergic rhinitis and its impact on asthma: ARIA workshop report. J Allergy Clin. Immunol. 108(5 Suppl.), S147-S334 (2001).
2. Dykewicz MS, Fineman S, Skoner DP et al. Diagnosis and management of rhinitis: complete guidelines of the joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 81(5 Pt 2), 478-518 (1998).
3. Rossoff LJ, Stempel DA, Alam R. The health and economic impact of rhinitis. Am. J. Manag. Care 3(Suppl.), S8-S18 (1997).
4. Santos R, Cifaldi M, Gregory C, Seitz P. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am. J. Manag. Care 5(Suppl.), S225-S234 (1999).
5. The UCB Institute of Allergy. European Allergy White Paper. Chapter 5: Socio-economic costs of allergic diseases. (1997).
6. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann. Allergy Asthma Immunol. 82(3), 296-305 (1999).
7. Vuurman EFPM, van Veggel LMA, Uiterwijk MMC, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann. Allergy 71(2), 121-126 (1993).
8. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat. Respir. Med. 4(6), 439-446 (2005).
9. Stull DE, Roberts L, Frank L, Heithoff K. Relationship of nasal congestion with sleep, mood, and productivity. Curr Med. Res. Opin. 23(4), 811-819 (2007).
10. Bousquet J, Van Cauwenberge P, Bachert C et al. Requirements for medications commonly used in the treatment of allergic rhinitis. Allergy 58(3), 192-197 (2003).
11. Bousquet J, van Cauwenberge P, Khaled NA et al. Pharmacologic and anti-IgE treatment of allergic rhinitis. ARIA update (in collaboration with GA2LEN). Allergy 61(9), 1086-1096 (2006).
12. International Rhinitis Management Working Group. International consensus report on diagnosis and management of rhinitis. Allergy 49(19 Suppl.), 1-34 (1994).
13. Dykewicz MS, Fineman S. Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann. Allergy Asthma Immunol. 81(5 Pt 2), 463-468 (1998).
14. van Cauwenberge P, Bachert C, Passalacqua G et al. Consensus statement on the treatment of allergic rhinitis. Allergy 55(2), 116-134 (2000).
15. Price D, Bond C, Bouchard J et al. International Primary Care Respiratory Group (IPCRG) guidelines: management of allergic rhinitis. Prim. Care Resp. J. 15(1), 58-70 (2006).
16. Plaut M, Valentine MD. Allergic rhinitis. N. Engl. J. Med. 353(18), 1934-1944 (2005).
17. Horak F. Seasonal allergic rhinitis: newer treatment approaches. Drugs 45(4), 518-527 (1993).
18. Ferguson BJ. Allergic rhinitis: options for pharmacotherapy and immunotherapy. Postgrad. Med. 101(5), 117-131 (1997).
19. Busse WW. Role of antihistamines in allergic disease. Ann. Allergy 72(4), 371-375 (1994).
20. Fireman P. Allergic rhinitis. In: Atlas of Allergies (2nd Edition). Fireman P, Slavin RG (Eds.), Mosby-Wolfe, Times-Mirror, London, UK, 9.1-9.18 (1996).
21. Suonpää J. Treatment of allergic rhinitis. Ann. Med. 28(1), 17-22 (1996).
22. Verster JC, Volkerts ER, van Oosterwijck AWAA et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J. Allergy Clin. Immunol. 111(3), 623-627 (2003).
23. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy 56(11), 1077-1080 (2001).
24. Kim K, Sussman G, Hébert J, Lumry W, Lutsky B, Gates D. Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 96(3), 460-465 (2006).
25. Black MJ, Remsen KA. Rhinitis medicamentosa. Can. Med. Assoc. J. 122(8), 881-884 (1980).
26. Bachert C. Persistent rhinitis - allergic or nonallergic? Allergy 59(Suppl. 76), 11-15 (2004).
27. American Academy of Allergy, Asthma and Immunology. The allergy report. Vol. 2. Diseases of the Atopic Diathesis. WI, USA (2000).
28. Bronsky E, Boggs P, Findlay S et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal rhinitis. J. Allergy Clin. Immunol. 96(2), 139-147 (1995).
29. Bertrand B, Jamart J, Marchal JL, Arendt C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology 34(2), 91-96 (1996).
30. Gastpar H, Nolte D, Aurich R et al. Comparative efficacy of azelastine nasal spray and terfenadine in seasonal and perennial rhinitis. Allergy 49(3), 152-158 (1994).
31. Davies RJ, Bagnall AC, McCabe RN, Calderon MA, Wang JH. Antihistamines: topical versus oral administration. Clin. Exp. Aallergy 26(Suppl. 3), 11-17 (1996).
32. Drouin MA, Yang WH, Horak F. Faster onset of action with topical levocabastine than with oral cetirizine. Mediators Inflamm. 4(Suppl.), S5-S10 (1995).
33. MedPointe Healthcare Inc.: Astelina® (azelastine hydrochloride) product information.
34. Novartis Ophthalmics: Livostino® (levocabastine hydrochloride ophthalmic suspension) product information.
35. Fokkens WJ, Godthelp T, Holm AF, Blom H, Klein-Jan A. Allergic rhinitis and inflammation: the effect of nasal corticosteroid therapy. Allergy 52(Suppl. 36), 29-32 (1997).
36. Erin EM, Zacharasiewicz AS, Nicholson GC et al. Topical corticosteroid inhibits interleukin-4, -5 and -13 in nasal secretions following allergen challenge. Clin. Exp. Allergy 35(12), 1608-1614 (2005).
37. Rak S, Jacobson MR, Sudderick RM et al. Influence of prolonged treatment with topical corticosteroid (fluticasone propionate) on early and late phase nasal responses and cellular infiltration in the nasal mucosa after allergen challenge. Clin. Exp. Allergy 24(10), 930-939 (1994).
38. Barton BE, Jakway JP, Smith SR, Siegel MI. Cytokine inhibition by a novel steroid, mometasone furoate. Immunopharmacol. Immunotaxicol. 13(3), 251-261 (1991).
39. + T cells. J. Allergy Clin. Immunol. 97, 288 (1996) (Abstract 423).
40. + T cells. J. Allergy Clin. Immunol. 100(4), 511-519 (1997).
41. Scadding GK. Corticosteroids in the treatment of pediatric allergic rhinitis. J. Allergy Clin. Immunol. 108(1 Suppl.), S59-S64 (2001).
42. Fowler PD, Gazis AG, Page SR, Jones NS. A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo - pituitary - adrenal axis and bone turnover in patients with nasal polyposis. Clin. Otolaryngol. Allied Sci. 27(6), 489-493 (2002).
43. Patel D, Ratner P, Clements D, Wu W, Faris M, Philpot E. Lack of effect on hypothalamic - pituitary - adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in adolescents and adults with perennial allergic rhinitis (PAR). J. Allergy Clin. Immunol. 119, S305 (2007) (Abstract 1191).
44. Tripathy I, Sterling R, Clements D, Wu W, Faris M, Philpot E. Lack of effect on hypothalmic - pituitary - adrenal (HPA) axis function by once-daily fluticasone furoate nasal spray (FFNS) 110 mcg in children with perennial allergic rhinitis (PAR). J. Allergy Clin. Immunol. 119, S232 (2007) (Abstract 909).
45. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic - pituitary - adrenal axis function in children with allergic rhinitis. Ann. Allergy Asthma Immunol. 93(1), 61-67 (2004).
46. Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 30(4), 317-326 (2007).
47. Di Lorenzo G, Pacor MI, Pellitteri ME et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin. Exp. Allergy 34(2), 259-267 (2004).
48. Pullerits T, Praks L, Ristioja V, Lötvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J. Allergy Clin. Immunol. 109(6), 949-955 (2002).
49. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am. J. Med. 116(5), 338-344 (2004).
50. Ädelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J. Allergy Clin. Immunol. 106(2), 253-259 (2000).
51. Chervinsky P, Casale T, Townley R et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 91(2), 160-167 (2003).
52. Genentech, Inc.: Xolair® (omalizumab) product information.
53. Davydov L. Omalizumab (Xolair) for treatment of asthma. Am. Fam. Physician 71(2), 341-342 (2005).
54. Schering Corporation: Nasonex® (mometasone furoate monohydrate) product information.
55. Onrust SV, Lamb HM. Mometasone furoate: a review of its intranasal use in allergic rhinitis. Drugs 56(4), 725-745 (1998).
56. Schenkel E. Features of mometasone furoate nasal spray and its utility in the management of allergic rhinitis. Expert Opin. Pharmacother. 4(9), 1579-1591 (2003).
57. Mygind N, Nielsen LP, Hoffmann HJ et al. Mode of action of intranasal corticosceroids. J Allergy Clin. Immunol. 108(1 Suppl.), S16-S25 (2001).
58. Smith CL, Kreutner W. In vitro glucocorticoids receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung 48(9), 956-960 (1998).
59. Linsley PS, Ledbetter JA. The role of CD28 receptor during T cell responses to antigen. Annu. Rev. Immunol. 11, 191-212 (1993).
60. Corrigan CJ, Kay AB. T cells and eosinophils in the pathogenesis of asthma. Immunol. Today 13(12), 501-506 (1992).
61. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
62. Crocker IC, Church MK, Newton S, Townley RG. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. Ann. Allergy Asthma Immunol. 80(6), 509-516 (1998).
63. Crocker IC, Zhou CY, Bewtra AK, Kreutner W, Townley RG. Glucocorticoids inhibit leukotriene production. Ann. Allergy Asthma Immunol. 78(5), 497-505 (1997).
64. Frieri M, Therattil J, Chavarria V et al. Effect of mometasone furoate on early and late phase inflammation in patients with seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 81(5 Pt 1), 431-437 (1998).
65. Meltzer EO, Jalowayski AA, Orgel HA, Harris AG. Subjective and objective assessments in patients with seasonal allergic rhinitis: effects of therapy with mometasone furoate nasal spray. J. Allergy Clin. Immunol. 102(1), 39-49 (1998).
66. Lee DKC, Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJ. Systemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis. Br. J. Clin. Pharmacol. 55(3), 310-313 (2003).
67. Daley-Yates PT, Kunka RL, Yin Y, Andrews SM, Callejas S, Ng C. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 60(4), 265-268 (2004).
68. Affrime MB, Cuss F, Padhi D et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J. Clin. Pharmacol. 40(11), 1227-1236 (2000).
69. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Ther. 19(6), 1330-1339 (1997).
70. Bronsky EA, Aaronson DW, Berkowitz RB et al. Dose ranging study of mometasone filroate (Nasonex) in seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 79(1), 51-56 (1997).
71. Berkowitz RB, Roberson S, Zora J et al. Mometasone furoate nasal spray is rapidly effective in the treatment of seasonal allergic rhinitis in an outdoor (park), acute exposure setting. Allergy Asthma Proc. 20(3), 167-172 (1999).
72. Berkowitz RB, Bernstein DI, LaForce C et al. Onset of action of mometasone furoate nasal spray (NASONEX® in seasonal allergic rhinitis. Allergy 54(1), 64-69 (1999).
73. Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone faroate aqueous nasal spray (Nasonex™) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 51(8), 569-576 (1996).
74. Gawchik S, Goldstein S, Prenner B, John A. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann. Allergy Asthma Immunol. 90(4), 416-421 (2003).
75. Berger WE, Nayak AS, Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann. Pharmacother. 39(12), 1984-1989 (2005).
76. Meltzer EO, Berger WE, Berkowitz RB et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J. Allergy Clin. Immunol. 104(1), 107-114 (1999).
77. Graft D, Aaronson D, Chervinsky P et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J. Allergy Clin. Immunol. 98(4), 724-731 (1996).
78. Pitsios C, Papadopoulos D, Kompoti E et al. Efficacy and safety of mometasone furoate vs. nedocromil sodium as prophylactic treatment for moderate/severe seasonal allergic rhinitis. Ann. Allergy Asthma Immunol. 96(5), 673-678 (2006).
79. Drouin M, Yang WH, Bertrand B et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann. Allergy Asthma Immunol. 77(2), 153-160 (1996).
80. Mandl M, Nolop K, Lutsky BN, and Participants in the 194-079 Study Group. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann. Allergy Asthma Immunol 79(4), 370-378 (1997).
81. Bende M, Carrillo T, Vóna I, Castel-Branco MdG, Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 88(6), 617-623 (2002).
82. Tsang RKY, Tong MCF, Woo JKS, Van Hasselt CA. A prospective study on the efficacy of mometasone furoate monohydrate aqueous nasal spray on Chinese patients with allergic rhinitis. Otolaryngol. Head Neck Surg. 128(4), 497-502 (2003).
83. Dibildox J. Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: results of recent clinical trials. J. Allergy Glin. Immunol. 108(1 Suppl.), S54-S58 (2001).
84. Schenkel E, LaForce C, Gates D. Mometasone fitroate nasal spray in seasonal allergic rhinitis: effective in relieving ocular symptoms. Allergy Clin. Immunol. Int. 19(2), 50-53 (2007).
85. Bielory L, Danzig MR, Gates D. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone faroate. Ann. Allergy Asthma Immunol. In press (2008).
86. Lebel B, Bousquet J, Morel A, Chanal I, Godard P, Michel F-B. Correlation between symptoms and the threshold for release of mediators in nasal secretions during nasal challenge with grass-pollen grains. J. Allergy Clin. Immunol. 82(5 Pt 1), 869-777 (1988).
87. Data on file, Schering-Plough Corporation.
88. O'Brien F, Minshall E, Nolop K et al. Histological and immunocytochemical assessment by nasal biopsy of mometasone furoate nasal spray in perennial rhinitis. J. Allergy Clin. Immunol. 99(Pt 1), S498 (1997) (Abstract 2016).
89. Minshall E, Ghaffar O, Cameron L et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 118(5), 648-654 (1998).
90. Davies RJ, Nelson HS. Once-daily mometasone furoate nasal spray: efficacy and safety of a new intranasal glucocorticoid for allergic shinitis. Clin. Ther. 19(1), 27-38 (1997).
91. Brannan MD, Seiberling M, Cutler DL, Cuss FM, Affrime MB. Lack of systemic activity with intranasal mometasone furoate. J. Allergy Clin. Immunol. 97(Pt 3), 198 (1996) (Abstract 62).
92. Brannan MD, Herron JM, Reidenberg P, Affrime MB. Lack of HPA axis suppression following 36 days of intranasal mometasone furoate. Ann. Allergy Asthma Immunol. 78, 154 (1997) (Abstract P207).
93. Schenkel EJ, Skoner DP, Bronsky EA et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone faroate aqueous nasal spray. Pediatrics 105(2), e22 (2000).
94. Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr. Asthma Allergy Immunol. 19(3), 146-153 (2006).
95. Agertoft L, Pedersen P. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J. Allergy Clin. Immunol. 104(5), 948-952 (1999).
96. Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat. Respir. Med. 4(4), 289-296 (2005).